You are viewing a single comment's thread.

view the rest of the comments →

NOMOCHOMO ago

@asolo @carmencita haven't pinged ya'll in a while. Hope you're both well

carmencita ago

Doing just fine 😊 thanks for asking

Wondering how @ASolo is too.

Vindicator ago

Carmencita, are you aware you being lured into participating in a doxxing attempt? You might want to "view context" before replying to notifications. Please note that Chomo is doing exactly what ES did when he was sucking you into his brigading.

NOMOCHOMO ago

https://voat.co/v/pizzagate/3686169/22751670

I think it's hilarious they believe Crensch would use his real name.

I didn't dox anyone. https://voat.co/v/anon/3679254

Nor am I attempting to.

But I do find it funny that colin rensch is involved in

https://www.asbmb.org/asbmb-today/science/090119/closing-in-on-a-cure

stem cells.

When muscle cells die, the myogenic stem cells, or satellite cells, that sit beneath the lowest layer of skin are activated to create new muscle cells. By targeting this source of muscle fibers, Amy Wagers and colleagues at the Harvard Stem Cell Institute believe that genome-level repairs to the dystrophin gene could be made permanent and produce the full-length proteins that microdystrophin approximates.

“If you don’t also modify the gene in satellite cells, in the sense that these cells seed replacement of the muscle fibers, there’s the possibility that, over time, the modified genes that are therapeutic will get diluted in muscle by the fusion into the fibers of new, unmodified satellite cells,” Wagers said.

In a paper published in the journal Cell Reports in June, Wagers and colleagues reported that when satellite cells in mice were targeted with a variety of muscle-specific adeno-associated viruses containing a gene that codes for the Cre protein, which is able to activate a simple fluorescent gene-editing reporter system by cutting at Lox sites, the fluorescent protein was expressed in more than 60% of the cells.

“We looked to see whether we were also getting modification in the precursors to muscle fibers in the muscle stem cells,” Wagers said. “And we got evidence for that using two different genetic systems, that one could modify the DMD gene in satellite cells.”

In addition to the need to validate the safety and efficacy of the CRISPR–Cas9 system, Wagers has concerns about the immune system’s tendency to clear adeno-associated viruses from the body after its first encounter with them.

*“Can you get enough efficiency with a single dose? Or can you somehow circumvent the immune response so that you can do multiple dosing?” she said. “Those are sort of related

Why didn't the FDA want to approve this treatment?

https://www.managedhealthcareexecutive.com/pharmacy/controversy-surrounds-exondys-51-approval-what-know